Related Experiment Videos
Thymic dysfunction in histiocytosis-X.
The American Journal of Pediatric Hematology/Oncology
|January 1, 1987
Summary
Histiocytosis-X patients show suppressor T cell deficiencies, potentially linked to thymus dysfunction. Thymic hormone therapy, like thymulin, may help by stimulating these crucial immune cells.
Area of Science:
- Immunology
- Endocrinology
- Pediatric Pathology
Background:
- Histiocytosis-X is associated with suppressor T cell deficiencies.
- Evidence suggests a potential role for thymus dysfunction in the disease pathogenesis.
- Low serum thymic factor (FTS) levels are observed in affected patients.
Purpose of the Study:
- To investigate the immunological defect in histiocytosis-X.
- To explore the role of thymic factor (FTS) and its inhibition in the disease.
- To evaluate the potential of thymic hormone therapy.
Main Methods:
- In vitro correction of T cell deficiency using calf thymic extract and thymostimulin.
- Measurement of serum thymic factor (FTS) levels.
- Analysis of plasma factors inhibiting FTS biological activity.
Main Results:
- Suppressor T cell deficiency in some histiocytosis-X patients was corrected by thymic extracts.
- Low serum thymic factor (FTS) levels were detected in patients.
- Patient plasma contained inhibitors of FTS biological activity in vitro.
Conclusions:
- Histiocytosis-X may stem from a primary immunodeficiency syndrome involving thymic dysfunction.
- Thymic hormone therapy, particularly with thymulin, shows promise for treatment by enhancing suppressor T cells.